VIDEO: Speaker presents data on povetacicept in autoimmune glomerulonephritis
Click Here to Manage Email Alerts
Key takeaways:
- Povetacicept is a dual antagonist of the B-cell activating factor and a proliferation-inducing ligand cytokines.
- A low dose of povetacicept led to a more than 60% reduction in galactose-deficient IgA1.
PHILADELPHIA — Researchers from Alpine Immune Sciences Inc. presented clinical findings using povetacicept to treat autoimmune glomerulonephritis during ASN Kidney Week.
Povetacicept (ALPN-303, Alpine Immune Sciences Inc.) is a dual antagonist of the B-cell activating factor and a proliferation-inducing ligand cytokines, which contribute to pathogenesis of multiple autoimmune diseases in the activation, differentiation and/or survival of B cells, including antibody-secreting cells, T cells and innate immune cells.
In the treatment of IgA nephropathy, a low dose of povetacicept led to a more than 60% reduction in the disease-related biomarker galactose-deficient IgA1, Sreedhar A. Mandayam, MD, MPH, MBAFASN, a professor in the section of nephrology in the division of internal medicine at the University of Texas MD Anderson Cancer Center in Houston and principal investigator in the trial, told Healio. The therapy also resulted in stable renal function assessed by eGFR.
“This is exciting that the combination of [a proliferation-inducing ligand] APRIL and [B-cell activating factor] BAFF blockade in patients with autoimmune kidney disease is probably going to be the future for patients with IgA nephropathy,” Mandayam said.
Reference:
Alpine Immune Sciences presents initial clinical data on povetacicept in autoimmune glomerulonephritis in a late-breaking poster session at the American Society of Nephrology Kidney Week 2023. https://ir.alpineimmunesciences.com/news/news-details/2023/Alpine-Immune-Sciences-Presents-Initial-Clinical-Data-on-Povetacicept-in-Autoimmune-Glomerulonephritis-in-a-Late-Breaking-Poster-Session-at-the-American-Society-of-Nephrology-Kidney-Week-2023/default.aspx. Published Nov. 2, 2023. Accessed Nov. 27, 2023.
Collapse
Click Here to Manage Email Alerts